Zymfentra Pen (2 Pack)(Infliximab-Dyyb)
Medicare prescription drug cost, prescriptions and prescribers, 2024
$1.5M
Medicare cost, 2024
$1.5M
Medicare cost, 2024
Medicare drug plans spent $1.5 million on Zymfentra Pen (2 Pack) (infliximab-dyyb) in 2024, for 184 prescriptions and refills filled by 55 patients. At about $8,385 per prescription it is a high-cost drug.
Medicare cost, 2024
$1.5M
Prescriptions
184
$8,385.08 per claim
Patients
55
56 prescribers
Total spending, 2024
$1.5M
$28,051.91 per patient
Questions and answers
How much does Medicare spend on Zymfentra Pen (2 Pack)?
Medicare prescription drug plans paid $1.5M for Zymfentra Pen (2 Pack) in 2024, for 184 prescriptions and refills to 55 patients. The average cost per claim was $8,385.08.
Which state spends the most on Zymfentra Pen (2 Pack)?
Texas had the highest Medicare cost for Zymfentra Pen (2 Pack) in 2024: $286K for 27 claims, followed by Florida ($224K).
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2024 | 56 | 184 | 55 | $1.5M |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Celltrion USA, | 184 | $1.5M |
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through June 2026, 29,059 side-effect reports named infliximab-dyyb, the active ingredient of Zymfentra Pen (2 Pack) (reports from 2015 on). 23,998 of them (82.6%) were serious, 703 named a death and 7,127 named a hospital stay. The reactions named most often were off label use, condition aggravated and intentional product use issue. 17,550 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
29,059
2,894 in 2025 (-31.6% from 2024)
Serious
82.6%
23,998 reports
Deaths named
703
2.4% of reports
Hospital stays
7,127
24.5% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Zymfentra Pen (2 Pack)?
29,059 reports from 2015 through June 2026 named infliximab-dyyb, the active ingredient of Zymfentra Pen (2 Pack). 23,998 of them (82.6%) were serious, 703 named a death and 7,127 named a hospital stay.
What are the most reported side effects of Zymfentra Pen (2 Pack)?
15,200 reports named off label use, the reaction named most often, followed by condition aggravated (10,706) and intentional product use issue (8,396). In the last 5 years the reaction named most often was off label use (9,157 reports). A report can name several reactions.
How many side-effect reports named Zymfentra Pen (2 Pack) in 2025?
2,894 reports were received in 2025 (-31.6% from 2024). 2026 so far: 1,295 reports through June 2026, and more keep arriving late.
Do side-effect reports prove that Zymfentra Pen (2 Pack) caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Zymfentra Pen (2 Pack) caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with infliximab-dyyb: Inflectra, Zymfentra, Zymfentra (2 Pack)
- Makers on the stock market:
PFE·PFE drug pipeline - Drug approvals (2 approvals on file for infliximab-dyyb) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (infliximab-dyyb) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.